09/05/2007
Ablatherm-HIFU Localized Prostate Cancer Clinical Study Resumes at Virginia Urology Center

EDAP TMS S.A. announced the continuation of its US Phase II/III clinical trial with treatment of an additional two patients at Virginia Urology Center, Richmond, Virginia. Anthony Sliwinski, MD, and David Miller, MD, are leading the study at the site.
"We continue to work with our centers accelerating recruitment of patients eligible to participate in this important study of a new but well documented method for treating localized prostate cancer," said Marc Oczachowski, CEO of EDAP. "Ablatherm-HIFU has a 10-year record of successful outcomes and low side effects with significant clinical studies already published.

>> Read full article

03/05/2007
EDAP and Duke Medical Restart Ablatherm-HIFU Localized Prostate Cancer Clinical Study. Duke Performs First Treatments under EDAP Study Sponsorship

"EDAP's more than 10 years of experience in HIFU therapy plus extensive peer reviewed and published clinical references demonstrate the potential of HIFU in the US. We continue to show solid growth outside the US where Ablatherm-HIFU use is already approved and growing as Ablatherm achieves standard of care status in the treatment of localized prostate cancer in Europe, the only HIFU device able to demonstrate such progress and market adoption. Ablatherm is the true HIFU leader in Europe and clearly the preferred HIFU system. This success outside the US is due to our clear commitment to clinical excellence, and we have absolute confidence our US…"

>> Read full article

27/03/2007
EDAP Reports on its Great Success at European Association of Urology Congress. Longest HIFU Clinical Results Confirm Addition to Standard of Care Protocols; Symposium Confirms Ablatherm Strong Outcomes

The next three presentations were based on long-term data, all with a minimum of five years follow-up and reaching as far as 10 years of experience data. Dr F.G. Murat of HEH in Lyon, presented a long term results study of 140 low and intermediate risk patients. Ablatherm efficiency on long-term results showed an overall survival rate at 90% at 5 years, 83% at 8 years with no death related to HIFU. Also confirming the validity of Ablatherm-HIFU, 86% of the patients did not require any form of a salvage treatment at 5 Yrs and 79% at 8 years.

>> Read full article